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Background:  Despite the availability of iron chelators, iron-overload cardiomyopathy is still responsible for high mortality in thalassemia 
patients. We previously demonstrated that Fe2+ uptake into thalassemic heart is mainly mediated by T-type and L-type calcium channels 
(TTCC, LTCC). However, the direct comparisons of therapeutic efficacy among TTCC and LTCC blockers, and iron chelators under iron-
overload condition have never been investigated.
methods:  Iron-overload condition was induced in genetically altered β-thalassemic (BKO) mice and wild-type (WT) mice by high iron 
diet consumption for 4 months. Then, LTCC blocker (amlodipine), TTCC blocker (efonidipine) and 3 iron chelators; desferoxamine (DFO), 
deferiprone (DFP) and deferasirox (DFX) were given for 1 month. Cardiac and mitochondrial function and biochemical parameters were 
determined.
results:  Treatment with LTCC and TTCC blockers and iron chelators showed similar efficacy in improving cardiac function and reducing 
cardiac iron deposit and mitochondrial dysfunction in iron-overload mice (Fig A, B, D). However, TTCC blocker, but not LTCC blocker, 
reduced liver iron, liver malondialdehyde (MDA) and plasma MDA similar to that of 3 iron chelators (Fig C).
conclusion:  In iron-overload mice, TTCC blocker provided cardiac, liver and systemic protection similar to those found in 3 iron chelators, 
suggesting that TTCC blocker could be an alternative and superior to LTCC blocker in treating iron-overload cardiomyopathy.
 
